The DEDICATE trial of TAVR vs SAVR, more on renal denervation, inclisiran, and marketing disguised as science are the topics John Mandrola, MD, discusses in today’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
www.medscape.com/twic
I. TAVR vs SAVR
TAVI Comparable With SAVR in Lower-Risk Aortic Stenosis
www.medscape.com/viewarticle/...

• DEDICATE www.nejm.org/doi/full/10.1056...
• Partner 3 www.nejm.org/doi/full/10.1056...
• Evolut Low Risk www.nejm.org/doi/full/10.1056...
• Barili meta-analysis doi.org/10.1093/ejcts/ezab516
II. Renal Denervation
Alcohol-Mediated Renal Denervation Promising in Hypertension
www.medscape.com/viewarticle/...

• TARGET 1 www.ahajournals.org/doi/10.11...
III. Inclisiran
Earlier Inclisiran Gives Better Long-Term LDL Reductions
www.medscape.com/viewarticle/...

• VICTORIAN INITIATE Trial www.jacc.org/doi/10.1016/j.ja...
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. www.medscape.com/author/bob-h...
Questions or feedback, please contact news@medscape.net